SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Van Bechtel I, Cieza A, Boonen A, Stucki G, Zochling J, Braun J, et al. Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. J Rheumatol 2006; 33: 247583.
  • 2
    Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 1824.
  • 3
    Van der Heijde D, Lie E, Kvien TK, Sieper J, van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 18118.
  • 4
    Machado PM, Landewe RB, van der Heijde DM. Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: Results from OMERACT 10. J Rheumatol 2011; 38: 15026.
  • 5
    Machado P, van der Heijde D. How to measure disease activity in axial spondyloarthritis? Curr Opin Rheumatol 2011; 23: 33945.
  • 6
    Pedersen SJ, Sorensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors. Ann Rheum Dis 2011; 70: 137581.
  • 7
    Pedersen SJ, Sorensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2010; 69: 106571.
  • 8
    Eder L, Chandran V, Shen H, Cook RJ, Gladman DD. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 2010; 69: 21604.
  • 9
    Pham T, Landewe R, van der Linden S, Dougados M, Sieper J, Braun J, et al. An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. Ann Rheum Dis 2006; 65: 16205.
  • 10
    Kvien TK, Heiberg, Lie E, Kaufmann C, Mikkelsen K, Nordvag BY, et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005; 23 Suppl 39: S188S94.
  • 11
    Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011; 70: 4753.
  • 12
    Van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis: progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999; 26: 9514.
  • 13
    Zochling J, Sieper J, van der Heijde D, Braun J. Development of a core set of domains for data collection in cohorts of patients with ankylosing spondylitis receiving anti-tumor necrosis factor-alpha therapy. J Rheumatol 2008; 35: 107982.
  • 14
    Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003; 62: 206.
  • 15
    Bodur H, Ataman S, Rezvani A, Bugdayci DS, Cevik R, Birtane M, et al. Quality of life and related variables in patients with ankylosing spondylitis. Qual Life Res 2011; 20: 5439.
  • 16
    Van der Heijde DM, Revicki DA, Gooch KL, Wong RL, Kupper H, Harnam N, et al. Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 2009; 11: R124.
  • 17
    Doward LC, McKenna SP, Meads DM, Twiss J, Revicki D, Wong RL, et al. Translation and validation of non-English versions of the Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire. Health Qual Life Outcomes 2007; 5: 7.
  • 18
    Pham T, van der Heijde DM, Pouchot J, Guillemin F. Development and validation of the French ASQoL questionnaire. Clin Exp Rheumatol 2010; 28: 37985.
  • 19
    Zhao LK, Liao ZT, Li CH, Li TW, Wu J, Lin Q, et al. Evaluation of quality of life using ASQoL questionnaire in patients with ankylosing spondylitis in a Chinese population. Rheumatol Int 2007; 27: 60511.
  • 20
    Lovas K, Geher P, Whalley D, McKenna S, Meads D, Kalo Z. Hungarian adaptation of a disease-specific quality-of-life questionnaire in patients with ankylosing spondylitis. Orv Hetil 2002; 143: 18937. In Hungarian.
  • 21
    Duruoz T, Doward LC, Cerrahoglu L, Turan Y, Yurtkuran M, Calis M, et al. Translation and validation of the Turkish version of the ankylosing spondylitis quality of life (ASQoL) Questionnaire [abstract]. Ann Rheum Dis 2008; 67 Suppl II: 623.
  • 22
    Jenks K, Treharne GJ, Garcia J, Stebbings S. The ankylosing spondylitis quality of life questionnaire: validation in a New Zealand cohort. Int J Rheum Dis 2010; 13: 3616.
  • 23
    Haywood KL, Garratt M, Jordan K, Dziedzic K, Dawes PT. Disease-specific, patient-assessed measures of health outcome in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) 2002; 41: 1295302.
  • 24
    Maksymowych WP, Richardson R, Mallon C, van der Heijde D, Boonen A. Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis. Arthritis Rheum 2007; 57: 1339.
  • 25
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 228691.
  • 26
    Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 134652.
  • 27
    Davis JC Jr, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48: 32306.
  • 28
    Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al, for the Atlas Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 213646.
  • 29
    Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62: 81724.
  • 30
    Van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 9058.
  • 31
    Cohen JD, Cunin P, Farrenq V, Oniankitan O, Carton L, Chevalier X, et al. Estimation of the Bath Ankylosing Spondylitis Disease Activity Index cutoff for perceived symptom relief in patients with spondyloarthropathies. J Rheumatol 2006; 33: 7981.
  • 32
    Taylor AL, Balakrishnan C, Calin A. Reference centile charts for measures of disease activity, functional impairment, and metrology in ankylosing spondylitis. Arthritis Rheum 1998; 41: 111925.
  • 33
    Claudepierre P, Sibilia J, Goupille P, Flipo RM, Wendling D, Eulry F, et al. Evaluation of a French version of the Bath Ankylosing Spondylitis Disease Activity Index in patients with spondyloarthropathy. J Rheumatol 1997; 24: 19548.
  • 34
    Waldner A, Cronstedt H, Stenstrom CH. The Swedish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. Scand J Rheumatol Suppl 1999; 111: 106.
  • 35
    Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, et al. A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis. J Rheumatol 1999; 26: 9615.
  • 36
    Akkoc Y, Karatepe AG, Akar S, Kirazli Y, Akkoc N. A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity. Rheumatol Int 2005; 25: 2804.
  • 37
    Brandt J, Westhoff G, Rudwaleit M, Listing J, Zink A, Braun J, et al. Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany. Z Rheumatol 2003; 62: 26473. In German.
  • 38
    Bonisch A, Ehlebracht-Konig I. The BASDAI-D—an instrument to defining disease status in ankylosing spondylitis and related diseases. Z Rheumatol 2003; 62: 25163. In German.
  • 39
    El Miedany Y, Youssef S, Mehanna A, Shebrya N, Abu GS, El Gaafaly M. Defining disease status in ankylosing spondylitis: validation and cross-cultural adaptation of the Arabic Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and the Bath Ankylosing Spondylitis Global score (BASG). Clin Rheumatol 2008; 27: 60512.
  • 40
    Cardiel MH, Londono JD, Gutierrez E, Pacheco-Tena C, Vazquez-Mellado J, Burgos-Vargas R. Translation, cross-cultural adaptation, and validation of the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Dougados Functional Index (DFI) in a Spanish speaking population with spondyloarthropathies. Clin Exp Rheumatol 2003; 21: 4518.
  • 41
    Pimentel-Santos FM, Santos H, Barcelos A, Cunha I, Branco JC, Lopes Ferreira P. Portuguese version of the Bath indices for ankylosing spondylitis patients: a cross-cultural adaptation and validation. Ann Rheum Dis 2010; 69 Suppl 3: 697.
  • 42
    Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) 1999; 38: 87882.
  • 43
    Van Tubergen A, Debats I, Ryser L, Londono J, Burgos-Vargas R, Cardiel MH, et al. Use of a numerical rating scale as an answer modality in ankylosing spondylitis–specific questionnaires. Arthritis Rheum 2002; 47: 2428.
  • 44
    Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study. J Rheumatol 2005; 32: 805.
  • 45
    Dougados M, Luo MP, Maksymowych WP, Chmiel JJ, Chen N, Wong RL, et al, for the Atlas Study Group. Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial. Arthritis Rheum 2008; 59: 55360.
  • 46
    Tubach F, Pham T, Skomsvoll JF, Mikkelsen K, Bjorneboe O, Ravaud P, et al. Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis. Arthritis Rheum 2006; 55: 9603.
  • 47
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 22815.
  • 48
    Stone MA, Pomeroy E, Keat A, Sengupta R, Hickey S, Dieppe P, et al. Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration. Rheumatology (Oxford) 2008; 47: 12138.
  • 49
    Boonen A, de Vet H, van der Heijde D, van der Linden S. Work status and its determinants among patients with ankylosing spondylitis: a systematic literature review. J Rheumatol 2001; 28: 105662.
  • 50
    Wei JC, Wong RH, Huang JH, Yu CT, Chou CT, Jan MS, et al. Evaluation of internal consistency and re-test reliability of Bath ankylosing spondylitis indices in a large cohort of adult and juvenile spondylitis patients in Taiwan. Clin Rheumatol 2007; 26: 168591.
  • 51
    Ruof J, Sangha O, Stucki G. Comparative responsiveness of 3 functional indices in ankylosing spondylitis. J Rheumatol 1999; 26: 195963.
  • 52
    Eyres S, Tennant A, Kay L, Waxman R, Helliwell PS. Measuring disability in ankylosing spondylitis: comparison of bath ankylosing spondylitis functional index with revised Leeds Disability Questionnaire. J Rheumatol 2002; 29: 97986.
  • 53
    Jones SD, Calin A, Steiner A. An update on the Bath Ankylosing Spondylitis Disease Activity and Functional Indices (BASDAI, BASFI): excellent Cronbach's alpha scores. J Rheumatol 1996; 23: 407.
  • 54
    Madsen OR, Rytter A, Hansen LB, Suetta C, Egsmose C. Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients. Clin Rheumatol 2010; 29: 84954.
  • 55
    Haywood KL, Garratt AM, Dawes PT. Patient-assessed health in ankylosing spondylitis: a structured review. Rheumatology (Oxford) 2005; 44: 57786.
  • 56
    Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346: 134956.
  • 57
    Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001; 44: 1805.
  • 58
    Heikkila S, Viitanen JV, Kautiainen H, Kauppi M. Does improved spinal mobility correlate with functional changes in spondyloarthropathy after short-term physical therapy? J Rheumatol 2000; 27: 29424.
  • 59
    Van Tubergen A, Landewe R, van der Heijde D, Hidding A, Wolter N, Asscher M, et al. Combined spa–exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2001; 45: 4308.
  • 60
    Jones SD, Steiner A, Garrett SL, Calin A. The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 1996; 35: 6671.
  • 61
    Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 1994; 21: 16948.
  • 62
    Van der Heijde D, Landewe R, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 2008; 67: 48993.
  • 63
    Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 166775.
  • 64
    Machado P, Landewe R, Braun J, Hermann KG, Baker D, van der Heijde D. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010; 69: 146570.
  • 65
    Jones SD, Porter J, Garrett SL, Kennedy LG, Whitelock H, Calin A. A new scoring system for the Bath Ankylosing Spondylitis Metrology Index (BASMI) [letter]. J Rheumatol 1995; 22: 1609.
  • 66
    Heikkila S, Viitanen JV, Kautiainen H, Kauppi M. Functional long-term changes in patients with spondylarthropathy. Clin Rheumatol 2002; 21: 11922.
  • 67
    Shinjo SK, Goncalves R, Kowalski S, Goncalves CR. Brazilian-Portuguese version and applicability questionnaire of the mobility index for ankylosing spondylitis. Clinics (Sao Paulo) 2007; 62: 13944.
  • 68
    Tzelepis GE, Kalliakosta G, Tzioufas AG, Sfikakis PP, Mandros C, Boki KA, et al. Thoracoabdominal motion in ankylosing spondylitis: association with standardised clinical measures and response to therapy. Ann Rheum Dis 2009; 68: 96671.
  • 69
    Wanders A, Landewe R, Dougados M, Mielants H, van der Linden S, van der Heijde D. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 2005; 64: 98894.
  • 70
    Jauregui E, Conner-Spady B, Russell AS, Maksymowych WP. Clinimetric evaluation of the bath ankylosing spondylitis metrology index in a controlled trial of pamidronate therapy. J Rheumatol 2004; 31: 24228.
  • 71
    Dougados M, Gueguen A, Nakache JP, Nguyen M, Mery C, Amor B. Evaluation of a functional index and an articular index in ankylosing spondylitis. J Rheumatol 1988; 15: 3027.
  • 72
    Landewe R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009; 68: 8637.
  • 73
    Van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schiff M, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two–week, randomized, controlled study. Arthritis Rheum 2005; 52: 120515.
  • 74
    Ruof J, Sangha O, Stucki G. Evaluation of a German version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Dougados Functional Index (D-FI). Z Rheumatol 1999; 58: 21825.
  • 75
    Salaffi F, Stancati A, Silvestri A, Carotti M, Grassi W. Validation of the Italian versions of the Bath Ankylosing Spondylitis Functional Index (BASFI) and the Dougados Functional Index (DFI) in patients with ankylosing spondylitis. Reumatismo 2005; 57: 16173. In Italian.
  • 76
    Karatepe AG, Akkoc Y, Akar S, Kirazli Y, Akkoc N. The Turkish versions of the Bath Ankylosing Spondylitis and Dougados Functional Indices: reliability and validity. Rheumatol Int 2005; 25: 6128.
  • 77
    Kennedy LG, Edmunds L, Calin A. The natural history of ankylosing spondylitis. Does it burn out? J Rheumatol 1993; 20: 68892.
  • 78
    Averns HL, Oxtoby J, Taylor HG, Jones PW, Dziedzic K, Dawes PT. Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol 1996; 25: 13842.
  • 79
    Ward MM, Kuzis S. Validity and sensitivity to change of spondylitis-specific measures of functional disability. J Rheumatol 1999; 26: 1217.
  • 80
    Daltroy LH, Larson MG, Roberts NW, Liang MH. A modification of the Health Assessment Questionnaire for the spondyloarthropathies. J Rheumatol 1990; 17: 94650.
  • 81
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 82
    Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 2004; 50: 95360.
  • 83
    Hidding A, van der Linden S. Factors related to change in global health after group physical therapy in ankylosing spondylitis. Clin Rheumatol 1995; 14: 34751.
  • 84
    Hidding A, van der Linden S, Gielen X, de Witte L, Dijkmans B, Moolenburgh D. Continuation of group physical therapy is necessary in ankylosing spondylitis: results of a randomized controlled trial. Arthritis Care Res 1994; 7: 906.
  • 85
    Viitanen JV, Heikkila S. Functional changes in patients with spondylarthropathy: a controlled trial of the effects of short-term rehabilitation and 3-year follow-up. Rheumatol Int 2001; 20: 2114.
  • 86
    Queiro R, Sarasqueta C, Belzunegui J, Gonzalez C, Figueroa M, Torre-Alonso JC. Psoriatic spondyloarthropathy: a comparative study between HLA-B27 positive and HLA-B27 negative disease. Semin Arthritis Rheum 2002; 31: 4138.
  • 87
    Shinjo SK, Goncalves R, Kowalski S, Goncalves CR. Brazilian-Portuguese version of the Health Assessment Questionnaire for Spondyloarthropathies (HAQ-S) in patients with ankylosing spondylitis: a translation, cross-cultural adaptation, and validation. Clin Rheumatol 2007; 26: 12548.
  • 88
    Ozcan E, Yilmaz O, Tutoglu A, Bodur H. Validity and reliability of the Turkish version of the Health Assessment Questionnaire for the Spondyloarthropathies. Rheumatol Int. E-pub ahead of print.
  • 89
    Moncur C. Ankylosing spondylitis measures. Arthritis Care Res 2003; 49 Suppl: S197209.